Squarepoint Ops LLC Grows Stake in Haemonetics Corporation $HAE

Squarepoint Ops LLC lifted its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 194.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 86,124 shares of the medical instruments supplier's stock after purchasing an additional 56,843 shares during the quarter. Squarepoint Ops LLC owned about 0.19% of Haemonetics worth $6,459,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Corient Private Wealth LP increased its stake in Haemonetics by 120.8% in the 2nd quarter. Corient Private Wealth LP now owns 64,693 shares of the medical instruments supplier's stock worth $4,852,000 after acquiring an additional 35,389 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Haemonetics in the 2nd quarter valued at about $315,000. California State Teachers Retirement System boosted its position in shares of Haemonetics by 7,550.6% during the 2nd quarter. California State Teachers Retirement System now owns 4,024,650 shares of the medical instruments supplier's stock valued at $301,849,000 after acquiring an additional 3,972,044 shares during the last quarter. Tsfg LLC purchased a new position in shares of Haemonetics during the second quarter worth about $134,000. Finally, Two Sigma Securities LLC purchased a new position in shares of Haemonetics during the second quarter worth about $356,000. Institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on HAE shares. Raymond James Financial raised their target price on shares of Haemonetics from $105.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, September 3rd. Barrington Research increased their price target on shares of Haemonetics from $95.00 to $118.00 and gave the stock an "outperform" rating in a report on Wednesday, August 19th. Mizuho raised their price objective on shares of Haemonetics from $85.00 to $90.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Citigroup lifted their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Haemonetics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $99.78.

Haemonetics Stock Down 1.8%

Shares of HAE opened at $101.31 on Friday. The firm has a market cap of $4.61 billion, a P/E ratio of 49.66, a P/E/G ratio of 2.07 and a beta of 0.54. The stock has a 50 day simple moving average of $89.90 and a two-hundred day simple moving average of $72.81. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $109.57.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, topping the consensus estimate of $1.08 by $0.06. The firm had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business's revenue was up 5.5% compared to the same quarter last year. During the same period last year, the firm posted $1.10 earnings per share. On average, analysts forecast that Haemonetics Corporation will post 5.29 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.